Ana-maria Tanase
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial.
Journal: American journal of respiratory and critical care medicine
Published: July 06, 2023
Living with sarcoidosis: Virtual roundtable dialogue with patients and healthcare professionals.
Journal: Respiratory medicine
Published: December 21, 2022
Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM study.
Journal: Respiratory medicine
Published: December 15, 2022
Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma.
Journal: Journal of asthma and allergy
Published: October 11, 2022
Long-term safety of once-daily indacaterol acetate/glycopyrronium bromide/mometasone furoate high-dose, and indacaterol acetate/mometasone furoate high-dose, in Japanese patients with inadequately controlled asthma: Results from two open-label, 52-week studies.
Journal: The Journal of asthma : official journal of the Association for the Care of Asthma
Published: March 29, 2022
A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma.
Journal: Advances in therapy
Published: October 29, 2021
One time a day mometasone/indacaterol fixed-dose combination versus two times a day fluticasone/salmeterol in patients with inadequately controlled asthma: pooled analysis from PALLADIUM and IRIDIUM studies.
Journal: BMJ open respiratory research
Published: October 28, 2020
Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study.
Journal: The Lancet. Respiratory medicine
Published: January 20, 2020
Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
Journal: The Lancet. Respiratory medicine
Published: January 20, 2020
Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers.
Journal: Pulmonary pharmacology & therapeutics
Published: January 15, 2020
A randomized, double-blind study to compare the efficacy and safety of two doses of mometasone furoate delivered via Breezhaler® or Twisthaler® in patients with asthma.
Journal: Pulmonary pharmacology & therapeutics
Published: October 23, 2019
Last Updated: 09/26/2026